Reductions in body weight following chronic central opioid receptor subtype antagonists during development of dietary obesity in rats Journal Article


Authors: Cole, J. L.; Leventhal, L.; Pasternak, G. W.; Bowen, W. D.; Bodnar, R. J.
Article Title: Reductions in body weight following chronic central opioid receptor subtype antagonists during development of dietary obesity in rats
Abstract: Acute administration of long-acting general opioid antagonists reduces body weight and food intake in rats. In contrast, chronic administration of short-acting general opioid antagonists produces transient effects. The present study evaluated whether chronic central administration of selective long-acting antagonists of mu (beta-funaltrexamine, BFNA, 20 μg), mu1 (naloxonazine, 50 μg), delta1([d-Ala2,Leu5,Cys6]-enkephalin, DALCE, 50 μg), delta2 (naltrindole isothiocyanate, NTII, 20 μg) or kappa (nor-binaltorphamine, NBNI, 20 μg) opioid receptor subtypes altered weight and intake of rats exposed to a palatable diet of pellets, fat, milk and water, relative to pellet-fed and diet-fed controls. Diet-fed rats receiving chronic vehicle injections significantly increased weight (7-10%) and intake over the 11-day time course. Weight was significantly reduced over the time course in rats administered either BFNA (9%), naloxonazine (12%), DALCE (7%) or NTII (6%). Initial weight reductions failed to persist following chronic NBNI. All antagonists chronically reduced fat intake, but did not systematically alter total intake, pellet intake or milk intake relative to the pattern of weight loss. These data indicate that central mu, mu1, delta1, delta2, and, to a lesser degree, kappa receptors mediate long-term opioid modulation of weight even in animals maintained on diets that ultimately result in dietary obesity. © 1995 Elsevier Science B.V. All rights reserved.
Keywords: controlled study; unclassified drug; nonhuman; animal; animal experiment; animal model; body weight; obesity; weight reduction; feeding; food intake; time factors; eating; rat; rats; rats, sprague-dawley; opioid; naloxone; opiate receptor; beta funaltrexamine; naltrindole; naltrexone; naloxonazine; dietary fats; narcotic antagonists; mu receptor; intracerebroventricular drug administration; norbinaltorphimine; male; priority journal; article; enkephalin derivative; support, u.s. gov't, p.h.s.; kappa receptor; leucine enkephalin[2 dextro alanine 6 cysteine]; delta receptor; dietary obesity; naltrindole derivative
Journal Title: Brain Research
Volume: 678
Issue: 1-2
ISSN: 0006-8993
Publisher: Elsevier Science, Inc.  
Date Published: 1995-04-24
Start Page: 168
End Page: 176
Language: English
DOI: 10.1016/0006-8993(95)00181-o
PUBMED: 7620885
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 28 August 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gavril W Pasternak
    414 Pasternak